A pipette and receptacles used in stem cell research. (Photo: CI Photos)The talk at the California stem cell agency this week was of ”boiling the ocean,” the meaning of “unlikely” and “DEI.” All of which involves how $5.5 billion in taxpayer dollars will be used over the next decade or so.
A scientist at work in a biological lab. (Photo: anyaivanova)California voters have apparently approved spending $5.5 billion more on stem cell research over the next 10 to 15 years and significantly broadening the scope of its state stem cell agency, according to unofficial figures this morning.
Robert Klein, left, and CIRM board member Jeff Sheey, right. At center is Board Vice Chair Art Torres. (Photo: California Stem Cell Report)The two men once worked together over the last 16 years to spend $3 billion in state funds on stem cell research in California. This week, however, they were very publicly on opposite sides of a ballot initiative to spend $5.5 billion more. The initiative is Proposition 14, which would require the state to borrow the additional billions.
California Gov. Gavin Newsom just before a meeting in Sacramento. ((Photo: Matt Gush, cvia Shutterstock)Gov. Gavin Newsom, long a supporter of the California stem cell agency, today endorsed Proposition 14, the November ballot measure to give the agency $5.5 billion more and save it from financial extinction.
A cancer stem cell researcher in the laboratory. (Photo: science photo, via Shutterstock)A $5.5 billion stem cell bond measure qualified this afternoon for the November ballot, but the campaign to win voter approval is facing an array of hurdles that its supporters never envisioned last summer when they were formulating the initiative.
Robert Klein, who spent six years as the state stem cell agency's chairman, addresses issues related to the November ballot initiative. (Photo: David Jensen, California Stem Cell Report)The folks who are trying to save the $3 billion California stem cell agency from financial extinction are using a well-worn technique that goes back to ancient Egypt, at least by some accounts. It is expensive, depending on what you are peddling, and generates a return as low as 1 percent. It is direct mail, but with a significant twist.
A laboratory researcher examines cancer stem cells. (Image: science photo, via Shutterstock)Backers of a $5.5 billion stem cell research proposal in California today have once again missed a self-imposed, but critical deadline as they continue to struggle with securing enough signatures to place the measure on the November ballot.
A signature gatherer in Ventura during the 2018 election cycle. (Photo: Michael Gordon, via Shutterrstock)Backers of a $5.5 billion stem cell research initiative in California have suspended their efforts to gather signatures to place it on the November ballot, but are expressing confidence that the proposal will qualify. The campaign said it had run afoul of statewide bans on public gatherings.
A clinical researcher with a multi-pipette arrangement of cancer stem cells. (Photo: Science Photo, via Shutterstock)One of the nation’s leading regenerative medicine industry groups is touting multi-billion dollar savings that may be achieved with the type of stem cell and gene therapies that are being developed with cash from California’s financially beleaguered stem cell program.
Stem cells for treating cancer in microtubes. (Image: Science Photo, via Shutterstock)Backers of the financially stressed California stem cell agency yesterday filed their proposed ballot measure to refinance the agency with $5.5 billion if voters approve it in November 2020. The complex, 30-page initiative would also restructure a number of aspects of the agency and provide for financial assistance for patients and their families who might be involved in clinical trials.